<DOC>
	<DOC>NCT01863433</DOC>
	<brief_summary>This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated influenza vaccine containing the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged between 18 and 60 years.</brief_summary>
	<brief_title>A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males or females aged between 18 and 60 years at the time of vaccination. Females of childbearing potential (i.e., ovulating, premenopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the study. Females of childbearing potential must return a negative urine pregnancy test result prior to vaccination with the vaccine. Known hypersensitivity to a previous vaccination with influenza vaccine or allergy to eggs, ovalbumin, chicken protein, neomycin, polymyxin, or any components of the vaccine. Clinical signs of an active infection. A clinically significant medical condition. Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months preceding study entry. Females who are pregnant or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>